Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III

Abstract

Based on the first favourable results of adjuvant therapy of 5FU plus levamisole in Dukes C colonic cancer in 1990, we conducted a prospective trial. 1029 patients were randomised to receive one year 5FU plus levamisole or no further treatment following curative surgery for stage II or III colon (n = 730) or rectal cancer (n = 299). 45% were in stage II and 55% in stage III. With a median follow-up of 4 years and 9 months a significant reduction in odds of death (25%, SD 9%, P = 0.007) was observed for those with adjuvant treatment (65% at 5 year) compared to the observation group (55%). Improved relative survival was present in stage III (56% vs 44%), and in stage II patients (78% vs 70%). In rectal cancer a non-significant difference in disease-free or overall survival was observed. Distant metastases developed in 76%, while local recurrence alone occurred in 14%. An early start of adjuvant treatment (< 4 weeks) did not affect results. Compliance to 5FU plus levamisole was 69%. Severe toxicity did not occur. In conclusion, one year 5FU plus levamisole was of benefit in stage II and III colonic cancer; in rectal cancer a significant positive effect could not be demonstrated.

References 13

1. 1.

   Buyse M., Zeleniuch-Jacquotte A., Chalmers T. C. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA. 1988;259(24):3571-3578.

   Not in our library

2. 2.

   Fisher B., Wolmark N., Rockette H., Redmond C., Deutsch M., Wickerham D. L., Fisher E. R., Caplan R., Jones J., Lerner H. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80(1):21-29.

   Not in our library10.1093/jnci/80.1.21

3. 3.

   Frykholm G. J., Glimelius B., Påhlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum. 1993;36(6):564-572.

   Not in our library10.1007/bf02049863

4. 4.

   Krook J. E., Moertel C. G., Gunderson L. L., Wieand H. S., Collins R. T., Beart R. W., Kubista T. P., Poon M. A., Meyers W. C., Mailliard J. A. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709-715.

   Not in our library10.1056/nejm199103143241101

5. 5.

   Laurie J. A., Moertel C. G., Fleming T. R., Wieand H. S., Leigh J. E., Rubin J., McCormack G. W., Gerstner J. B., Krook J. E., Malliard J. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989;7(10):1447-1456.

   Not in our library10.1200/jco.1989.7.10.1447

6. 6.

   Marijnen C. A., Nagtegaal I. D., Klein Kranenbarg E., Hermans J., van de Velde C. J., Leer J. W., van Krieken J. H., Pathology Review Committee and the Cooperative Clinical Investigators. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol. 2001;19(7):1976-1984.

   Not in our library10.1200/jco.2001.19.7.1976

7. 7.

   Moertel C. G., Fleming T. R., Macdonald J. S., Haller D. G., Laurie J. A., Goodman P. J., Ungerleider J. S., Emerson W. A., Tormey D. C., Glick J. H. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352-358.

   Not in our library10.1056/nejm199002083220602

8. 8.

   Moertel C. G., Fleming T. R., Macdonald J. S., Haller D. G., Laurie J. A., Tangen C. M., Ungerleider J. S., Emerson W. A., Tormey D. C., Glick J. H. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122(5):321-326.

   Not in our library10.7326/0003-4819-122-5-199503010-00001

9. 9.

   O'Connell M. J., Laurie J. A., Kahn M., Fitzgibbons R. J., Erlichman C., Shepherd L., Moertel C. G., Kocha W. I., Pazdur R., Wieand H. S. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16(1):295-300.

   Not in our library10.1200/jco.1998.16.1.295

10. 10.

    O'Connell M. J., Mailliard J. A., Kahn M. J., Macdonald J. S., Haller D. G., Mayer R. J., Wieand H. S. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15(1):246-250.

    Not in our library10.1200/jco.1997.15.1.246

11. 11.

    Treurniet-Donker A. D., van Putten W. L., Wereldsma J. C., Bruggink E. D., Hoogenraad W. J., Roukema J. A., Snijders-Keilholz A., Meijer W. S., Meerwaldt J. H., Wijnmaalen A. J. Postoperative radiation therapy for rectal cancer. An interim analysis of a prospective, randomized multicenter trial in The Netherlands. Cancer. 1991;67(8):2042-2048.

    Not in our library10.1002/1097-0142(19910415)67:8<2042::aid-cncr2820670806>3.0.co;2-4

12. 12.

    Wolmark N., Rockette H., Fisher B., Wickerham D. L., Redmond C., Fisher E. R., Jones J., Mamounas E. P., Ore L., Petrelli N. J. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11(10):1879-1887.

    Not in our library10.1200/jco.1993.11.10.1879

13. 13.

    Wolmark N., Rockette H., Mamounas E., Jones J., Wieand S., Wickerham D. L., Bear H. D., Atkins J. N., Dimitrov N. V., Glass A. G. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17(11):3553-3559.

    Not in our library10.1200/jco.1999.17.11.3553

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.